These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
288 related articles for article (PubMed ID: 27923516)
1. Therapy-related myelodysplastic syndromes, or are they? Abou Zahr A; Kavi AM; Mukherjee S; Zeidan AM Blood Rev; 2017 May; 31(3):119-128. PubMed ID: 27923516 [TBL] [Abstract][Full Text] [Related]
2. A review of therapy-related myelodysplastic syndromes and acute myeloid leukaemia (t-MDS/AML) in Irish patients: a single centre experience. Maung SW; Burke C; Hayde J; Walshe J; McDermott R; Desmond R; McHugh J; Enright H Hematology; 2017 Jul; 22(6):341-346. PubMed ID: 28196450 [TBL] [Abstract][Full Text] [Related]
3. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. Darrington DL; Vose JM; Anderson JR; Bierman PJ; Bishop MR; Chan WC; Morris ME; Reed EC; Sanger WG; Tarantolo SR J Clin Oncol; 1994 Dec; 12(12):2527-34. PubMed ID: 7989926 [TBL] [Abstract][Full Text] [Related]
4. Chromosomal abnormalities in women with breast cancer after autologous stem cell transplantation are infrequent and may not predict development of therapy-related leukemia or myelodysplastic syndrome. Martínez-Climent JA; Comes AM; Vizcarra E; Benet I; Arbona C; Prósper F; Solano C; García Clavel B; Marugán I; Lluch A; García-Conde J Bone Marrow Transplant; 2000 Jun; 25(11):1203-8. PubMed ID: 10849534 [TBL] [Abstract][Full Text] [Related]
6. Current therapy of myelodysplastic syndromes. Zeidan AM; Linhares Y; Gore SD Blood Rev; 2013 Sep; 27(5):243-59. PubMed ID: 23954262 [TBL] [Abstract][Full Text] [Related]
7. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management. Garcia-Manero G Am J Hematol; 2015 Sep; 90(9):831-41. PubMed ID: 26294090 [TBL] [Abstract][Full Text] [Related]
8. Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium. Zeidan AM; Al Ali N; Barnard J; Padron E; Lancet JE; Sekeres MA; Steensma DP; DeZern A; Roboz G; Jabbour E; Garcia-Manero G; List A; Komrokji R Leukemia; 2017 Jun; 31(6):1391-1397. PubMed ID: 28111463 [TBL] [Abstract][Full Text] [Related]
10. A case of treatment-related myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemotherapy with autologous stem cell transplantation for non-Hodgkin's lymphoma. Jang GD; Kim SW; Suh CW; Kim EK; Bahng HS; Jeong YH; Park IG; Kim WK; Kim SH; Suh EJ; Park CJ; Ji HS; Lee JS J Korean Med Sci; 2002 Aug; 17(4):555-9. PubMed ID: 12172056 [TBL] [Abstract][Full Text] [Related]
11. Selection of Patients With Myelodysplastic Syndrome for Allogeneic Hematopoietic Stem Cell Transplantation. Mishra A; Anasetti C Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S49-52. PubMed ID: 27521324 [TBL] [Abstract][Full Text] [Related]
12. Therapy-related myelodysplastic syndrome after autologous stem cell transplantation for breast cancer. Nichols G; de Castro K; Wei LX; Griffin M; Lin N; Oratzi A; Murty VV; Troxel A; Vahdat L; Hesdorffer C Leukemia; 2002 Sep; 16(9):1673-9. PubMed ID: 12200680 [TBL] [Abstract][Full Text] [Related]
13. Epidemiology of myelodysplastic syndromes: Why characterizing the beast is a prerequisite to taming it. Zeidan AM; Shallis RM; Wang R; Davidoff A; Ma X Blood Rev; 2019 Mar; 34():1-15. PubMed ID: 30314642 [TBL] [Abstract][Full Text] [Related]
15. Diagnosis of secondary myelodysplastic syndromes (MDS) following autologous transplantation should not be based only on morphological criteria used for diagnosis of de novo MDS. Amigo ML; del Cañizo MC; Rios A; Garcia MA; Caballero MD; Martin A; Bermejo N; Vilches P; San Miguel JF Bone Marrow Transplant; 1999 May; 23(10):997-1002. PubMed ID: 10373064 [TBL] [Abstract][Full Text] [Related]
16. Current State of the Art: Management of Higher Risk Myelodysplastic Syndromes. Komrokji RS Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S39-43. PubMed ID: 27521322 [TBL] [Abstract][Full Text] [Related]
17. Preparing Patients With Myelodysplastic Syndrome for Transplant When Is Pre-transplant Cytoreductive Therapy Appropriate? Wermke M; Gloaguen S; Platzbecker U Curr Hematol Malig Rep; 2015 Sep; 10(3):329-33. PubMed ID: 26126601 [TBL] [Abstract][Full Text] [Related]
19. Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends. Stahl M; Zeidan AM Expert Rev Hematol; 2017 Apr; 10(4):345-364. PubMed ID: 28277851 [TBL] [Abstract][Full Text] [Related]